Renzapride

From Wikipedia, the free encyclopedia

Chemical structure of Renzapride
Chemical structure of Renzapride

Renzapride is a full serotonin 5-HT4 receptor agonist, partial serotonin 5-HT3 and 5-HT2b receptor antagonist[1].

[edit] Clinical Uses

Renzapride is currently in Phase III clinical development in the United States for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is also potentially effective for irritable bowel syndrome with alternating stool pattern (IBS-A). It is being developed by Alizyme plc of the United Kingdom.

As of 23rd April 2008, Alizyme has ceased all development of this drug, after a Phase III trial in the U.S. did not show enough efficacy over placebo to justify further development.

[edit] References

  1. ^ Camilleri M., McKinzie S., Fox J., Foxx-Orenstein A., Burton D., Thomforde G., Baxter K. and Zinsmeister A. R. (2004). "Effect of Renzapride on Transit in Constipation-Predominant Irritable Bowel Syndrome", Clin. Gastroent. and Hepatology; 2:895-904
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.